Despite the availability of numerous pain medications, the current array of Food and Drug Administration-approved options falls short in adequately addressing pain states for numerous patients and consequently worsens the opioid crisis. Thus, it is imperative for basic research to develop novel and nonaddictive pain medications. Toward addressing this clinical goal, nalfurafine (NLF) was chosen as a lead and its structure-activity relationship (SAR) systematically studied through design, syntheses, and characterization of 24 analogues. Two analogues, and , showed longer durations of action than NLF in a warm-water tail immersion assay, produced effects primarily mediated by KOR and DOR, penetrated the blood-brain barrier, and did not function as reinforcers. Additionally, produced fewer sedative effects than NLF. Taken together, these results aid the understanding of NLF SAR and provide insights for future endeavors in developing novel nonaddictive therapeutics to treat pain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181328PMC
http://dx.doi.org/10.1021/acs.jmedchem.4c00646DOI Listing

Publication Analysis

Top Keywords

structure-activity relationship
8
nonaddictive pain
8
pain medications
8
novel nonaddictive
8
pain
5
systematic structure-activity
4
relationship study
4
study nalfurafine
4
nalfurafine analogues
4
analogues development
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!